Kornimate/medical-research-clean huggingface dataset:
galactose supplementation for the treatment of moghe

Conditions: Refractory Epilepsy; SLC35A2-CDG - Solute Carrier Family 35 Member A2 Congenital Disorder of Glycosylation

Summary: mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy (moghe) is a new entity frequently associated with refractory epilepsy and neurodevelopmental disorders. recently, it has been associated to slc35a2 (solute carrier family 35 member a2) brain mosaic pathogenic variants. in addition, patients with germline slc35a2 pathogenic variants improve with galactose supplementation. therefore, the investigators aim to elucidate whether d-galactose as an add-on treatment might improve epilepsy and developmental outcomes in patients with moghe.


Eligibility criteria:
inclusion criteria: * moghe diagnosis at histopathological examination of the epilepsy surgery tissue. * epilepsy refractoriness or ongoing epileptiform activity at eeg. exclusion criteria: * allergy to galactose or supplement components.
omnigen in acute chemical eye injuries

Conditions: Acute Chemical Eye Injuries

Summary: evaluation of the role of omnigen in acute chemical eye injuries

prospective interventional study included patients with different degrees of acute chemical eye injuries were treated by omnigen and followed up for one month

Eligibility criteria:
inclusion criteria: * acute chemical eye injury exclusion criteria: * absent or shallow fornices * symblepharon interfering with lens placement

Keywords: amniotic membrane chemical eye injury
hoboe: a phase 3 study of adjuvant triptorelin and tamoxifen, letrozole, or letrozole and zoledronic acid in premenopausal patients with breast cancer.

Conditions: Breast Cancer

Summary: the hoboe study was amended in november 2009, and, after reaching enrollment of the first 500 patients, the study began recruiting premenopausal patients only. the primary objective of the extended study is to compare disease free survival in premenopausal patients with early breast cancer. patients receive triptorelin and are randomized in a 1:1:1 fashion to receive tamoxifen or letrozole, or letrozole + zoledronic acid. the purpose of the hoboe study, version 1, was to compare the adjuvant hormonal therapy treatments of tamoxifen, letrozole and letrozole + zoledronate for their effects on bone loss in breast cancer patients. postmenopausal and premenopausal patients were eligible, the latter also receiving monthly triptorelin. upon reaching the enrollment of the first 500 patients in march 2010, the study began recruiting premenopausal patients only.


Eligibility criteria:
inclusion criteria: * histological diagnosis of breast cancer * surgical resection of breast cancer (breast conserving surgery or mastectomy) * no evidence of disease * indication for adjuvant hormonal therapy (er and/or pgr positive with ihc exam in at least 1% of primary tumor cells, according to st. gallen criteria) * patient age at least 18 years * written informed consent . premenopausal status defined as lmp within 12 months of randomization (fsh, lh will not be considered as determinants of menopausal status due the chemotherapy induced reversible ovarian suppression) please note that patients who have received neoadjuvant or adjuvant chemotherapy and/or locoregional radiation therapy may be included in the study exclusion criteria: * performance status (ecog)\>2. * previous or concomitant malignancy (with the exception of adequately treated nonmalignant skin cancer and carcinoma in situ of the uterine cervix * metastatic breast cancer * creatinine \> 1.25 times the value of upper normal limit * pregnant or lactating females * clinical or radiologic evidence of bone fractures * treatment with systemic cortisone therapy within 12 months prior to randomization * treatment with drugs that could alter bone metabolism (calcitonin, mithramycin, gallium nitrate) within 2 weeks prior to randomization * previous treatment with tamoxifen or aromatase inhibitors * ast and/or alt \> 3 times the value of upper normal limit with clinical and laboratory findings that indicate a grade of hepatic insufficiency that could potentially increase the risk of assuming letrozole * any concomitant conditions that would, in the investigator's opinion, contraindicate the use of any of the drugs used in this study * inability to provide informed consent * inability to comply with followup * patient undergoing invasive dental work at time of baseline evaluation or foreseen during the course of adjuvant therapy

Keywords: early breast cancer adjuvant therapy premenopause premenopausal menopausal status postmenopause bone mineral density hormone sensitive aromatase inhibitors letrozole disease-free survival
a modified surgical approach to women with obstetric anal sphincter tears

Conditions: Obstetric Surgical Procedures

Summary: long-term results after obstetric anal sphincter tears (ast) is poor. the investigators aim to improve the long-term outcome after ast in terms of symptoms of anal incontinence. a prospective study at, malmö university hospital. twenty-six women with at least grade 3b ast were classified and sutured in a systematic way, including separate suturing of the internal and external sphincter muscles with monofilament absorbable sutures. the principal outcome was a difference in anal incontinence score, based on six questions, between the study group and two control groups (women with prior ast \[n = 180\] and primiparous women delivered vaginally without ast \[n = 100\]).

the series was undertaken in advance of a planned prospective randomized controlled study. the study was approved by the research ethics committee of lund university and informed consent was obtained from all the women involved. twenty-six women presenting with at least a 3b rupture were recruited by one of the two surgeons (mj, pl). the modified technique included: 1. adoption of a structured way of describing the damage according to fornell an co-workers\[7\] and recommended by rcog.\[8\] grade 3a: any tear of the esm \ 50% grade 3c: related damage to the ism grade 4: related rupture of the anal mucosa 2. the use of monofilament resorbable suture material for all sutures in the mucosa or sphincter muscles. the anal mucosa was sutured with a continuous layer of 3.0 glycomer 631 (biosyn® ,tyco healthcare, mansfield, ma, usa); the ism with a continuous layer of 3.0 glycomer 631; and the esm (both superficial and profound portions) with interrupted end-to-end 2.0 glycomer 631 sutures. the perineal body was usually sutured with 2.0 or 3.0 lactomer (polysorb®, tyco healthcare, mansfield, ma, usa). 3. metronidazole 1.5g as a single iv injection and/or cefuroxime 1.5g iv during the procedure and 6 hours post-operative was usually given as prophylaxis. 4. all women were sutured under either regional anaesthesia (spinal, epidural, or pudendal) or general anaesthesia. thus, the modified procedure included both a new technique of suturing and the operation was performed by one of the two surgeons involved in the study. apart from this, all women were treated according to routine departmental practice.

Eligibility criteria:
inclusion criteria: * sphincter tear \> grad 3b exclusion criteria: * no

Keywords: sphincter obstetric tears long-term follow-up
a prospective, single-center, randomized, controlled, open-label, pilot study to compare the effectiveness and safety of diuretics add-on strategy in acute decompensated heart failure patients (dios ii)

Conditions: Congestive Heart Failure

Summary: to compare the effectiveness and safety of diuretics add-on strategy in chronic heart failure patients


Eligibility criteria:
inclusion criteria: 1. dyspnea at rest or minimal activity 2. tachypnea (respiratory rate \> 20/min) or rales or pulmonary edema on chest x-ray exclusion criteria: 1. hospitalization for acute heart failure decompensation 2. cardiogenic shock (systolic blood pressure \< 80mmhg) 3. need or plan for renal replacement therapy (dialysis, kidney transplant) 4. serum creatine level \> 2.5mg/dl 5. serum potassium (k+) \> 5.5mg/dl 6. age \> 80 years old or poor compliance patients 7. allergy, adverse drug reaction, hypersensitivity to any kinds of diuretics 8. life expectancy \< 6 months (e.g. metastatic malignancy, liver cirrhosis) 9. pregnancy or women at age of childbearing potential

Keywords: heart failure, diuretics, kidney, glomerular filtration rate
australian hepatitis and risk survey in prisons

Conditions: Hepatitis C; Hepatitis B; HIV Infections

Summary: the australian hepatitis and risk survey in prisons (aushep) is a national prison-based blood-borne virus (bbv) surveillance study. this biobehavioural survey involves point-of-care testing for hepatitis c (hcv) antibodies and rna (if antibody positive), hepatitis b surface antigens, hepatitis b surface antibodies, and hiv surface antibodies, and an interview-style survey on prior testing and treatment history and engagement in risk behaviours. the study will recruit approximately 2400 prisoner participants from 25 representative prisons across australia, annually.


Eligibility criteria:
inclusion criteria: * any remandee or sentenced prisoner who has provided informed consent is eligible to participate in the study. exclusion criteria: * individuals who are unable or unwilling to provide consent or abide by the requirements of the study, as assessed by the trained nurses. some individuals may be considered unable to provide consent or abide by the requirements of the study if they are: * too mentally unwell to provide consent * profoundly intellectually impaired * unable to speak english and comprehend the survey. those excluded from participating in the study will be referred to the local prison clinic service for standard of care.

Keywords: blood-borne viruses prisons surveillance
effects of miglitol on daily plasma glucose in type2 diabetes treated with insulin

Conditions: Type 2 Diabetes Mellitus

Summary: in this study, the effect of miglitol on daily plasma glucose will be evaluated in type 2 diabetic patients treated with insulin.


Eligibility criteria:
inclusion criteria: * type2 diabetes * postprandial plasma glucose levels ≧180mg/dl exclusion criteria: * type1 diabetes * ast(got) or alt(gpt) ≧100iu/l * creatinine ≧2.0mg/dl

Keywords: alpha-glucosidase inhibitor,insulin
superiority of perineoplasty as concomitant surgical procedure during pelvic organ prolapse repair

Conditions: Pelvic Organ Prolapse

Summary: the goal of this study is to evaluate whether adding perineoplasty is, in comparison to performing vaginal prolapse surgery without adding perineoplasty, superior with respect to efficacy and cost-effectiveness and non-inferior with respect to morbidity, in patients undergoing vaginal surgical correction of pelvic organ prolapse at 24 months after surgery.

preoperative measurements, performed at baseline: * patient characteristics (age, bmi, smoking, obstetric history) * physical examination including pop-q score. the genital hiatus (gh) at rest (as part of the pop-q) will be used to assess the wideness of the vaginal introitus. * pelvic floor distress inventory (pfdi-20) questionnaire and patient global impression of severity (pgi-s) * pelvic floor ultrasound 2dstudy measurements; * pelvic organ prolapse/urinary incontinence sexual questionnaire (pisq-ir), dutch perineal support questionnaire (dpsq), general quality of life (eq-5d-5l), medical consumption questionnaire (imcq) and productivity cost questionnaire (ipcq) * patient and surgeons considerations with respect to level iii repair; postoperative measurements: * regular physical check-up will be at 4-8 weeks after procedure. * physical examination including pop-q score * patient global impression of improvement score (pgi-i) * pelvic floor ultrasound 2d * imcq, ipcq, eq-5d-5l questionnaire extra follow up: * physical check-up 12 \& 24 months after surgery: * physical examination including pop-q score * pelvic floor ultrasound 2d * pfdi-20, pgi-i, dpsq, pisq-ir, imcq, ipcq, eq-5d-5l questionnaire

Eligibility criteria:
inclusion criteria: 1. female patient \>18 years of age 2. complaints of pelvic organ prolapse 3. indication for prolapse surgery (level i and/or level ii repair) 4. genital hiatus (gh) according to pop-q staging of ≥4 cm and ≤7 cm exclusion criteria: 1. unable to understand the dutch language 2. pregnancy at baseline or intendancy to become pregnant during the study period 3. patients with previous surgery for pop (previous mid urethral sling operations for urinary stress incontinence not excluded) 4. unwilling and / or incapable of giving informed consent

Keywords: pop prolapse perineoplasty
luminex-based assay to identify major ige-binding episode among ige-mediated wheat-allergic patient

Conditions: Wheat Allergy

Summary: this study will be using luminex-based peptide assay (lpa) to determine major ige-binding epitope among wheat allergic children to differentiate clinical phenotype.

luminex-based peptide assay (lpa) is a novel tool using machine learning techniques, developed to predict different degrees of food allergy has been successfully reported among cow's milk protein allergy. this technique provide a more precise and advanced adaptation from microarray-based immunoassay (mia). using this technique will aid us for the differentiation of clinical phenotypes of wheat-allergic patients. this study will be the first study to date using this technique aim to determine major ige-binding epitope among immediated-reaction of wheat allergic children to differentiate clinical phenotypes, and may lead to further study to develop the new therapeutic approach to wheat-allergic patients.

Eligibility criteria:
inclusion criteria 1. patients with ige-mediated wheat allergy, with one of the following criteria; 1.1 a convincing clinical history of the reactions within 4 hours after wheat ingestion during the past 12 months combined with positive skin prick test (spt) and/or the level of specific ige (sige) to wheat or 1.2 a positive oral food challenge (ofc) result to wheat during the past 12 months or 2. patients with wheat tolerant confirmed by negative oral food challenge (ofc) result to wheat during the past 12 months or 3. patients with ige-mediated wheat allergy and underwent wheat oral immunotherapy for at least 6 months or at the maintenance phase of the treatment exclusion criteria patients with delayed allergic reactions after wheat ingestion greater than 4 hours

Keywords: major allergen
effect of st. john's wort oil on skin moisture in intensive care patients

Conditions: Skin Moisture

Summary: the study was conducted to evaluate the effect of st. john's wort oil application on skin moisture in intensive care patients. the study is a prospective pre-test-post-test controlled experimental research.it has been observed that st. john's wort oil has an effect on the skin moisture of intensive care patients.

effect of st. john's wort oil on skin moisture in intensive care patients. the study was conducted to evaluate the effect of st. john's wort oil application on skin moisture in intensive care patients. the study is a prospective pre-test-post-test controlled experimental research. research data was collected at eskisehir city hospital, between september 1, 2023 and march 1, 2024. descriptive characteristics form, braden risk assessment scale, moisture meter device and st. john's wort oil were used to collect data. in the sample size power analysis of the study, the total number of samples was found to be 138 with test power ( 1-β) 0.80, α(alpha)=0.05, effect level 0.10. the research was conducted on a total of 140 patients, 70 in the experimental group and 70 in the control group. st. john's wort oil was applied to the experimental group and routine nursing care was applied to the control group for 21 days. independent sample t test, anova (repeated measures test), mann- whitney u test, wilcoxon test and pearson-χ 2 cross tables were used to evaluate the data.

Eligibility criteria:
inclusion criteria: * admission to intensive care due to internal diseases diagnosis * the patient is immobile * the area to be applied is determined as the coccyx and the tissue in this area must be intact. * no allergy to st. john's wort oil * no circulatory disorders in the applied area exclusion criteria: * having a complicated diagnosis such as cancer * having any disease that has spread to the entire skin * having an allergy to topical medications or plant extracts * the patient has different variations such as surgical operation and intensive care change (post-operative follow-up patient) * the patient has a diagnosis of a skin disease such as dermatitis * a wound in the coccyx area

Keywords: skin moisture pressure ulcer nursing st. john's wort oil
application for monitoring and evaluation of raynaud's phenomenon

Conditions: Raynaud Phenomenon

Summary: to evaluate the feasibility of using a smartphone application for monitoring and evaluation of raynaud's phenomenon.


Eligibility criteria:
inclusion criteria: * primary or secondary raynaud phenomenon clinically diagnosed by a physician * phone compatible with the application (most android smartphones) * non-opposition of participation in the study * affiliation to the social security scheme or beneficiary of such a scheme exclusion criteria: * subject under administrative or judicial supervision * subject not speaking and not understanding french

Keywords: smartphone application monitoring
a study to investigate the pharmacokinetic drug interactions between dutasteride and tadalafil in healthy male subjects

Conditions: Benign Prostate Hyperplasia

Summary: this is open-label, a randomized, crossover study to evaluate the safety and pharmacokinetic interaction after oral concomitant administration of dutasteride and tadalafil in healthy male volunteers.


Eligibility criteria:
inclusion criteria: * age 19 to 45 years * bmi score 19 kg/m2 to 28 kg/m2 * sbp \< 140 mmhg and ≤ 90 mmhg or dbp \< 90 mmhg and ≥ 50 mmhg * eligible according to the laboratory results of hematology, blood chemistry and urinalysis * voluntarily signed the informed consent form exclusion criteria: * gastrointestinal diseases or surgery which may affect absorption of the investigational products within 6 months * history of hypersensitivity * history of cardiovascular disease * history of degenerative retina disease * lactose intolerance * history of vision loss * clinically significant disorders of allergy, drug hypersensitivity reaction, hepatobiliary system, kidney, neurology, respiratory, hemato-oncology, endocrine, dermatology, urology, ophthalmology, psychiatry, musculo-skeletal system, immunology, otorhinolaryngology, and cardiovascular system * donated whole blood (transfusion, apheresis etc..) within 60 days * participated and administered the investigational products in other clinical trial within 90 days * taking drugs which may affect clinical trial within 30 days * excessive alcohol consumption (\> 3 units/week, 1 unit) * taking food which may affect clinical trial within 7 days * positive result from urinary test, serum test * not eligible due to other reasons including laboratory results * clinically significant disorders result from electrocardiography test * not eligible due to investigator's judgments

Keywords: dutasteride tadalafil
ctpvb for hepatectomy

Conditions: Pain Management; Paravertebral Block; Hepatectomy

Summary: moderate to severe postoperative pain often influence patients quality of recovery after hepatectomy. systemic opioids given with patient-controlled analgesia has been used after hepatectomy in many medical center, but the analgesic effect can be limited and undesirable side effects may bring about negative effects on patients recovery. regional block has been proved to improve patients postoperative recovery in many kinds of surgeries. the investigators therefore designed a prospective, randomized, subject and assessor blinded, parallel-group, placebo controlled study to test the hypothesis that continuous right thoracic paravertebral block increase patients quality of recovery score on the 7th postoperative day after hepatectomy in patients receiving i.v. patient-controlled analgesia (pca) with morphine.


Eligibility criteria:
inclusion criteria: * age 18-70 yrs * american society of anesthesiologists physical statusⅰ-ⅲ * undergo hepatectomy with j-shape subcostal incision * informed consent exclusion criteria: * a known allergy to the drugs being used * coagulopathy, on anticoagulants * analgesics intake, history of substance abuse * participating in the investigation of another experimental agent * inability to properly describe postoperative pain to investigators (eg, language barrier, neuropsychiatric disorder)
factor product utilization and health outcomes in patients with hemophilia

Conditions: Hemophilia A, Congenital; Hemophilia B, Congenital

Summary: recombinant factor viii fc (rfviiifc) and recombinant factor ix fc (rfixfc) are extended half-life coagulation factors approved by health canada in 2014 for the treatment of severe hemophilia a and b, respectively. the objectives of this observational study is to describe the change in annual factor consumption, clinical and patient-reported outcomes for patients who switch from recombinant factor viii (rfviii) and recombinant factor ix (rfix) to rfviiifc/ rfixfc in canada, and to explore clinicians' and patients' reasons for switching or not switching.


Eligibility criteria:
inclusion criteria: 1. males ≥12 years of age with severe and moderate congenital hemophilia a or b (baseline factor activity\<5%) 2. ability to understand the purpose and risks of the study and provide signed and dated informed consent or assent and authorization to use protected health information (phi) in accordance with national and local privacy regulations. exclusion criteria: 1. unable or unwilling to provide informed consent 2. patients with an existing bleeding disorder other than hemophilia a or b 3. history of hypersensitivity or severe allergic reactions to factor products 4. patients currently participating in a phase 1-3 study with another factor replacement product 5. unable to adhere to the study requirements based on the judgment of the prescribing physician (e.g. unable to enter accurate and timely infusion and bleeding records)

Keywords: hemophilia recombinant factor viii recombinant factor viii fc recombinant factor ix patient-reported outcomes recombinant factor ix fc